Global Graft Versus Host Disease (GvHD) Treatment Market Projected to Reach USD 5,960.7 Million by 2033 at a 8.2% of CAGR

Global Graft Versus Host Disease (GvHD) Treatment Market
Global Graft Versus Host Disease (GvHD) Treatment Market

The global Graft Versus Host Disease (GvHD) Treatments market is poised for substantial growth, with an estimated valuation of USD 2,713.6 million in 2023. According to market forecasts, the market is expected to expand at a robust Compound Annual Growth Rate (CAGR) of 8.2% over the forecast period from 2023 to 2033, reaching approximately USD 5,960.7 million by 2033.

Graft versus host disease (GvHD) is a common complication following hematopoietic cell transplantation (HCT) where the donor’s immune cells attack the recipient’s tissues. The market’s growth is driven by increasing adoption of corticosteroids and combination therapies, advancements in medical treatments, and rising awareness about GvHD management.

Your Insightful Report Sample With Your Work Email:
https://www.futuremarketinsights.com/reports/sample/rep-gb-1401

In December 2021, the US Food and Drug Administration approved Orencia (abatacept) for the management of GVHD in both adult and pediatric patients. Orencia is used to avoid autoimmune diseases as well as treat them. Through specific attachment to and modification of one of the key costimulation signals sent by these cells, this medicine circumvents the attack of T-cells, which are essential in acute GVHD.

As a result, T-cells are prevented from fully activating, hence preventing acute (GVHD). Surgeons are evaluating several new approaches to prevent (GVHD) in the future.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-1401

Key Takeaways:

  • The global graft versus host disease (GvHD) treatment market is expected to reach US$5.96 billion by 2033, growing at a CAGR of 8.2%.
  • Rising adoption of combination therapies and advancements in allogeneic hematopoietic cell transplant (HCT) are key growth drivers.
  • Newer medications like Jakafi and Rezurock offer improved efficacy for chronic GvHD compared to traditional treatments.

Recent improvements in acute graft-versus-host disease (GVHD) severity levels and overall survival rates may be advantageous for allogeneic hematopoietic cell transplant patients; nevertheless, a number of issues still need to be resolved. Furthermore, more recent drug approvals for the prevention and treatment of chronic (GVHD) include Jakafi and Rezurock, which may be more beneficial than earlier ones.

Key Segments Profiled in Market:

By Product:

  • Monoclonal antibodies
  • mTOR inhibitors
  • Tyrosine kinase inhibitors
  • Thalidomide
  • Etanercept

By Disease:

  • Acute Graft Versus Host Disease (aGvHD)
  • Chronic Graft Versus Host Disease (cGvHD)

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Obtain In-Depth Market Insights: Purchase Now to Access:
 https://www.futuremarketinsights.com/checkout/1401

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these